Citius Pharmaceuticals, Inc. (CTXR) Stock Price, Quote & News - Stock Analysis (2024)

FAQs

Citius Pharmaceuticals, Inc. (CTXR) Stock Price, Quote & News - Stock Analysis? ›

Citius Pharmaceuticals's analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

Citius Pharmaceuticals's analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

The average one-year price target for Citius Pharmaceuticals, Inc. is $4.08. The forecasts range from a low of $4.04 to a high of $4.20. A stock's price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings.

According to our current CTXR stock forecast, the value of Citius Pharmaceuticals shares will drop by -3.82% and reach $ 0.76159 per share by July 25, 2024.

Based on short-term price targets offered by two analysts, the average price target for Citius Pharmaceuticals, Inc. comes to $5.00. The forecasts range from a low of $4.00 to a high of $6.00. The average price target represents an increase of 437.63% from the last closing price of $0.93.

The average one-year price target for Nutex Health Inc. is $30.60. The forecasts range from a low of $30.30 to a high of $31.50.

Citius Pharmaceuticals (NASDAQ: CTXR) does not pay a dividend.

The Cryptex Finance price prediction for 2030 is between $ 6.63 on the lower end and $ 10.75 on the high end. Based on our CTX price prediction chart, the price of Cryptex Finance could gain 318.06% and reach $ 10.75 if it reaches the upper price target.

Largest shareholders include BlackRock Inc., Vanguard Group Inc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, IWM - iShares Russell 2000 ETF, Geode Capital Management, Llc, State Street Corp, VEXMX - Vanguard Extended Market Index Fund Investor Shares, FSSNX - Fidelity Small Cap Index Fund, IWN - ...

On average, Wall Street analysts predict that Citius Pharmaceuticals's share price could reach $5.00 by Jul 15, 2025. The average Citius Pharmaceuticals stock price prediction forecasts a potential upside of 437.06% from the current CTXR share price of $0.93.

What does Citius Pharmaceuticals do? ›

Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy.

CPRX Stock 12 Month Forecast

Based on 5 Wall Street analysts offering 12 month price targets for Catalyst Pharma in the last 3 months. The average price target is $27.33 with a high forecast of $29.00 and a low forecast of $26.00. The average price target represents a 60.86% change from the last price of $16.99.

Amarin Corporation Plc's analyst rating consensus is a Moderate Sell. This is based on the ratings of 2 Wall Streets Analysts.

TG Therapeutics stock has received a consensus rating of buy. The average rating score is and is based on 19 buy ratings, 5 hold ratings, and 3 sell ratings.

Broker Rating

Lexicon Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.)